TrialVaccine2015

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.

Virgil E J C Schijns et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.